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In Brief
Structurally designed EBV vaccine
candidates based on self-assembling
nanoparticles elicit potent and durable
virus-neutralizing antibodies that target
the receptor-binding site on the viral
envelope protein gp350, a site of
vulnerability, serving as a template to
develop an EBV vaccine and providing a
basis for immunofocusing through
rational vaccine design.
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Epstein-Barr virus (EBV) represents a major global
health problem. Though it is associated with infec-
tious mononucleosis and200,000 cancers annually
worldwide, a vaccine is not available. The major
target of immunity is EBV glycoprotein 350/220
(gp350) that mediates attachment to B cells
through complement receptor 2 (CR2/CD21). Here,
we created self-assembling nanoparticles that dis-
played different domains of gp350 in a symmetric
array. By focusing presentation of the CR2-binding
domain on nanoparticles, potent neutralizing anti-
bodies were elicited in mice and non-human
primates. The structurally designed nanoparticle
vaccine increased neutralization 10- to 100-fold
compared to soluble gp350 by targeting a function-
ally conserved site of vulnerability, improving vac-
cine-induced protection in a mouse model. This
rational approach to EBV vaccine design elicited
potent neutralizing antibody responses by arrayed
presentation of a conserved viral entry domain, a
strategy that can be applied to other viruses.INTRODUCTION
Epstein-Barr virus (EBV) infection is associated with multiple hu-
man diseases, including infectious mononucleosis (IM) and a
variety of malignancies. Burkitt and Hodgkin lymphoma, gastric,
and nasopharyngeal carcinoma are among the neoplasms
observed after infection, as are lymphoproliferative disorders.
The prevalence and the severity of these diseases underscore
the potential public health benefit of an EBV vaccine (Cohen
et al., 2011).1090 Cell 162, 1090–1100, August 27, 2015 ª2015 Elsevier Inc.Despite the morbidity associated with EBV, there are no pro-
phylactic vaccines, though the virus was isolated and identified
more than a half century ago (Epstein et al., 1964). Attempts to
develop a vaccine have focused on the viral major envelope
glycoprotein 350/220 (gp350), because it represents a principal
target of neutralizing antibodies in naturally infected individuals
(Hoffman et al., 1980; Thorley-Lawson and Geilinger, 1980;
Thorley-Lawson and Poodry, 1982). Prototype gp350-based
vaccines have induced protective immunity against EBV-medi-
ated lymphomas in a cottontop tamarin challenge model of
disease (Epstein et al., 1985) and more recently reduced infec-
tion in a rhesus macaque model in which both immunization
and challenge were performed using rhesus macaque lymphoc-
ryptovirus, a homolog of EBV (Sashihara et al., 2011). Selected
candidate prophylactic EBV vaccines have been evaluated in hu-
mans (Elliott et al., 2008; Gu et al., 1995; Moutschen et al., 2007;
Sokal et al., 2007). The only phase II trial of an EBV prophylactic
vaccine used recombinant soluble gp350with an AS04 adjuvant.
That vaccine demonstrated a 78% reduction in the rate of IM in
EBV-seronegative vaccine, but it did not protect against acquisi-
tion of primary infection (Sokal et al., 2007), limiting enthusiasm
for its further development.
EBV infects B cells by engaging viral gp350 to its primary re-
ceptor, complement receptor 2 (CR2/CD21) (Fingeroth et al.,
1984), or alternatively CR1 (CD35) (Ogembo et al., 2013). The
heterotrimeric viral glycoprotein complex, gH/gL/gp42, binds
to HLA class II molecules as a co-receptor on B cells, while
heterodimeric gH/gL andBMRF2 engage integrins as primary re-
ceptors to infect epithelial cells (Connolly et al., 2011; Hutt-
Fletcher, 2007; Tugizov et al., 2003). Although inhibition of any
of these viral glycoproteins by antibody or gene disruption pre-
vents or severely impairs viral infection of cells, the degree of
virus neutralization varies by antibody specificity and the target
cell type. A murine monoclonal antibody (mAb) 72A1 potently
neutralizes EBV infection of B cells (Hoffman et al., 1980), and
its predicted epitope on gp350 largely overlaps the inferred
binding site of CR2, suggesting a mechanism of neutralization
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Figure 1. Molecular Design of gp350-Based
Nanoparticles
(A) Assembled hybrid ferritin model (left) and en-
capsulin (right). Engineered insertion sites for
exogenous antigens are indicated as red spheres.
(B) Schematic representation of full-length gp350,
its truncated variants, and gp350-based nano-
particles. Domains I, II, and III of gp350 are color
coded in dark blue, sky blue, and pale blue,
respectively. Structurally undefined region and
transmembrane (TM)/cytoplasmic tail (CT) are
colored in gray and white, respectively. Hexa-
histidine tag (HIS), ferritin, and encapsulin are
colored in black, red, and green, respectively.
Amino acid (AA) position relative to full-length
gp350 is indicated at the bottom.
See also Figure S1.mediated by this antibody (Tanner et al., 1988). The mAb 72A1
also blocks the interaction of gp350 with CR1 (Ogembo et al.,
2013), further indicating that this epitope is functionally important
and hence an attractive vaccine target to prevent viral infection
of B cells, a principal target cell type of EBV. Here, we aimed
to elicit potent neutralizing antibodies to this epitope by
immunizing with a vaccine designed based on a rational under-
standing of structural biology and nanotechnology to optimize
presentation and recognition of this site of vulnerability.
RESULTS
Design and Expression of EBV gp350-Based
Nanoparticles
To display monomeric antigens on the surface of self-assem-
bling nanoparticles, we identified two potential platforms, ferritin
(Cho et al., 2009) and encapsulin (Sutter et al., 2008). Ferritins
form an octahedral cage consisting of 24 subunits, while encap-
sulin forms an icosahedron made of 60 identical subunits (T = 1).
Ferritins have been engineered for multiple purposes (Huard
et al., 2013; Ja¨a¨skela¨inen et al., 2007; Li et al., 2006; Meldrum
et al., 1992). Among these innovations, we have recently devel-
oped a platform to mount a viral trimeric glycoprotein at ferritin’s
3-fold axes, providing a basis for structure-based nanoparticu-
late immunogens (Kanekiyo et al., 2013). Comparison of ferritin
structures revealed that certain ferritins, including human light
chain (Wang et al., 2006) (PDB: 2FFX) and bullfrog lower subunit
(Trikha et al., 1995) (PDB: 1RCC), contained an NH2-terminal
extension that was not present in ferritin fromHelicobacter pylori
(Cho et al., 2009) (PDB: 3EGM). This NH2-terminal extension
makes the NH2-terminal residue project radially from the nano-
particle core, and the termini are evenly spaced on the surface.
Due to relatively high sequence homology between bullfrog
and human ferritins (62%), we were concerned that use of either
as a vaccine platform could induce an autoimmune reaction.
The overall architecture of ferritin subunits from different spe-
cies is largely similar, although the sequences ofH. pylori and hu-Cell 162, 1090–1100,man ferritins are diverse (18% and 24%
identity to human light and heavy chains,
respectively). To avoid the potential forvaccine-induced autoimmunity, we therefore fused the amino
terminal extension of bullfrog ferritin to H. pylori ferritin to build
a hybrid that has the antigen-attachment sites distributed evenly
on the surface (Figure 1A, left). Although encapsulin has not been
studied as a scaffold to present heterologous proteins on its sur-
face, we found that the COOH-terminal of encapsulin subunits
project outward from the particle core and are located proximal
to the 5-fold symmetry axis (Figure 1A, right). This allowed us to
create COOH-terminal fusion proteins to present foreign antigen
on the nanoparticle surface.
EBV gp350 is a type I transmembrane protein composed
of 907 amino acids, including an ectodomain, a transmem-
brane domain, and a cytoplasmic tail (Figures 1B and S1A).
We analyzed different gp350 truncation variants for their
ability to form nanoparticles and found that the smallest
gp350 variant (D12) failed to express on both ferritin and
encapsulin platforms, suggesting instability of this variant.
The largest variant (ectodomain) with ferritin was expressed;
however, a mixture of assembled and misassembled/disas-
sembled species was observed that excluded further use of
this construct (Figure S1B). Two truncation variants, termed
D2H6O and D123, expressed stably on the ferritin and encap-
sulin without disturbing self-assembly of the nanoparticles.
Although gp350 is extensively posttranslationally modified
by both N- and O-linked glycosylations (Machiels et al.,
2011; Serafini-Cessi et al., 1989), the shorter D123 trunca-
tion eliminates most of the ‘‘mucin-like’’ domain, which may
prevent recognition of gp350 by the immune system (Fig-
ure S1C), and hence D123 was selected for further studies.
The purified soluble gp350 proteins and D123 nanoparticles
were homogenous, as shown by size exclusion chromatog-
raphy (Figure 2A).
Antigenicity and Structural Integrity of EBV
gp350-Based Nanoparticles
We next examined the antigenicity of gp350 displayed on nano-
particles by using mAbs to gp350. mAb 72A1 (Hoffman et al.,August 27, 2015 ª2015 Elsevier Inc. 1091
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Figure 2. Biochemical and Antigenic Char-
acterization of gp350-Based Nanoparticles
(A) Size exclusion chromatography profiles of
soluble gp350 ectodomain, D123, and D123 nano-
particles. After affinity purification with Ni-NTA
(soluble gp350 proteins) or GNA lectin (D123-
ferritin and D123-encapsulin), proteins were sepa-
rated by size exclusion chromatography using a
Superdex 200 10/300 (soluble gp350 proteins)
(left) or a Sephacryl S-500 16/60 (D123 nano-
particles) column (right).
(B and C) Binding of anti-gp350 mAbs to purified
proteins was assessed by immunoprecipitation (B)
and ELISA (C). HC and LC indicate heavy and light
chains of antibody, respectively. Each symbol
represents mean ± SD.
See also Figure S2.1980) recognizes the CR2-binding site (CR2BS) of gp350 and
potently neutralizes virus, whereas mAb 2L10 (Luka et al.,
1984) is a non-neutralizing anti-gp350 antibody and does not
compete with 72A1. Both D123-ferritin and D123-encapsulin
were immunoprecipitated equivalently by 72A1 and 2L10, but
not by an irrelevant mAb C179 (Okuno et al., 1993) (Figure 2B).
Analogous to soluble gp350 ectodomain, the D123 nanoparticles
bound to 72A1 and 2L10; however, soluble D123 showed
reduced reactivity to both mAbs by ELISA (Figure 2C), suggest-
ing that the conformation of D123 was preserved on the nanopar-
ticles while that of soluble D123 was altered. This indicated that
the soluble form of D123 differed biochemically from either
gp350 ectodomain or D123 nanoparticles, although the overall
thermostability of these proteins was similar, as measured by
differential scanning calorimetry (Figure S2A). To assess
whether the D123 nanoparticles could bind to their cognate
ligand, we tested their binding to CR2 on human B cells by
flow cytometry. As expected, both soluble gp350 and D123
nanoparticles bound to CR2hi B cells, and the binding was
dependent on CR2 expression, as the CR2lo B cells and
T cells (CR2) showed weaker and no binding, respectively (Fig-
ure S2B). Preincubation of anti-CR2 antibody diminished the
binding of gp350 to CR2, indicating that the interaction was
mediated by CR2 (Figure S2B).
Electron microscopic (EM) analysis confirmed that the D123
and D2H6O nanoparticles formed monodispersed particles
with globular protrusions from both ferritin and encapsulin
nanoparticles (Figures 3A and S3). Cryo-EM reconstruction
further confirmed the symmetry of gp350 D123 on ferritin and
encapsulin nanoparticles (Figure 3A). The location of the
gp350 protrusions on the ferritin nanoparticles correlated with
the 2-fold symmetry and formed a dimer; however, the mono-
meric gp350 protrusions in the encapsulin nanoparticles are1092 Cell 162, 1090–1100, August 27, 2015 ª2015 Elsevier Inc.well separated (Figure 3A). Although
gp350 D123 is predicted to be highly gly-
cosylated, the dimer interface observed
in ferritin cryo-EM contains hydrophobic
patches that might be favored to form a
dimer. As expected, the inferred CR2BS
on the gp350 D123 is exposed on thesurface of ferritin and is readily accessible for immune recogni-
tion (Figure 3B).
Immunogenicity of EBV gp350-Based Nanoparticles
To characterize the antibody response elicited by soluble gp350
derivatives and D123 nanoparticles, mice were immunized with
5.0 mg of soluble gp350 ectodomain, D123, D123-ferritin, or
D123-encapsulin in the presence of Sigma Adjuvant System
(SAS) at weeks 0 and 3. After the first dose, antibody binding
to gp350 was detected in mice immunized with D123-ferritin
and D123-encapsulin (ELISA endpoint titers of 10
4.6 ± 0.1 and
104.4 ± 0.4, respectively). These titers were >100-fold higher
than those found in mice immunized with gp350 ectodomain
(Figure 4A). Antibodies to gp350 were also measured in a
luciferase immunoprecipitation system (LIPS) assay, which
has been shown to correlate well with EBV neutralization activity,
and in a virus neutralization assay using a GFP-reporter
virus (Sashihara et al., 2009) (Figure 4A). The second dose of
D123-ferritin or D123-encapsulin substantially increased gp350
antibody titers. The binding dissociation rate of anti-gp350 anti-
bodies in sera was also improved by 3- to 5-fold after the second
dose, as measured using biolayer interferometry (Figure S4A),
indicating that anti-gp350 antibodies showed greater affinity
maturation and bound more tightly to gp350 than antibodies eli-
cited after the first dose, as observed with other vaccines (Bach-
mann et al., 1997; Khurana et al., 2011; Lee et al., 2012). After the
second injection, gp350 ectodomain elicited anti-gp350 anti-
body titers only 2-fold lower than those in mice immunized
with D123-ferritin or D123-encapsulin; but the neutralization activ-
ity of the sera frommice immunized with gp350 ectodomain was
1,000-fold lower than that of sera from D123-ferritin or D123-en-
capsulin immunization groups (Figure 4A). This discrepancy was
also observed in the LIPS assay (Figure 4A). Immunization with
D123-ferritin D123-encapsulin
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Figure 3. Structural Characterization of
gp350-Based Nanoparticles
(A) Negative-stain transmission EM images (top)
and cryo-EM reconstruction model (bottom) of
D123 nanoparticles.
(B) Fit model of gp350 D123 protrusion on ferritin
nanoparticle. PDB entry 2H6O of gp350 (residues
4–425) was superimposed into cryo-EM density
map. Inferred CR2BS is indicated. EM density
maps of D123-ferritin and D123-encapsulin were
deposited into EMDB under accessions EMDB-
3025 and EMDB-6341, respectively.
See also Figure S3.soluble D123 elicited a negligible antibody response by ELISA,
LIPS, and virus neutralization assays, indicating that the mono-
meric form of this protein is much less immunogenic. No virus-
neutralizing antibody was induced by ferritin alone or ferritin
mixed with either soluble gp350 ectodomain or D123 in contrast
to immunization with D123-ferritin (Figure 4B). These data docu-
ment that a physical linkage of antigen to nanoparticle is required
for antigen-specific immune induction and show that ferritin
does not stimulate a non-specific adjuvant response. Immuniza-
tion with a 10-fold lower dose (0.5 mg) of D123-ferritin and D123-
encapsulin induced virtually the same gp350 ELISA, LIPS, and
neutralizing antibody titers in mice (Figure S4B).
Durability of Neutralizing Antibodies Elicited by
gp350-Based Nanoparticles
We next assessed the kinetics of virus-neutralizing antibody in
immunized mice. Two months after the second dose of vaccine
(week 11), the neutralizing antibody titers in mice receiving D123-
ferritin and D123-encapsulin declined about 10-fold from the
peak titers but then remained stable until 3 months after the sec-
ond dose without further immunization (Figure 4C). Neutralizing
antibody titers in mice immunized with gp350 ectodomain
were slightly increased over time but still remained at a low level
(101.3 ± 0.5) (Figure 4C). Mice were then immunized with a third
dose at week 16. The titers were increased by 33- and 26-fold
in D123-ferritin and D123-encapsulin, respectively (IC50 titers of
104.3 ± 0.2 and 103.7 ± 0.2, respectively) after boosting, and those
titers did not wane as rapidly as after a second dose and re-
mained high even after 3 months (IC50 titers of 10
3.7 ± 0.3 and
103.6 ± 0.2, respectively) (Figure 4C). The soluble gp350 ectodo-
main did not substantially enhance the neutralizing antibody
titers after three immunizations (Figure 4C). We again observed
similar titers and kinetics of neutralizing antibody in the lower-
dose (0.5 mg) groups immunized with D123-ferritin or D123-encap-
sulin (Figure S4C). Importantly, no cross-reactive antibodies to
autologous (i.e., murine) ferritin were observed even after three
immunizations with D123-ferritin in mice, consistent with previous
findings that tolerance to homologous ferritin is preserved (Kane-
kiyo et al., 2013) (Figure S4D).Cell 162, 1090–1100,Immunogenicity of gp350-Based
Nanoparticles in Non-human
Primates
To evaluate vaccine-induced immunity
in a species more closely related tohumans, we immunized cynomolgus macaques (Macaca fasci-
cularis). Monkeys were given 50 mg of gp350 ectodomain or
25 mg of either gp350 D123-ferritin or D123-encapsulin with adju-
vant (SAS) at weeks 0, 4, and 12. Because these monkeys are
naturally infected with a lymphocryptovirus that shares homol-
ogy with EBV, cross-neutralizing EBV antibody was found in all
monkeys prior to immunization (IC50 titers from 10
1.1 to 102.0)
(Figure 5A). Nevertheless, the neutralizing antibody titers
increased after two doses (week 6) with either D123 nanoparticle,
and these titers were further enhanced by 119- and 25-fold from
the baseline after a third dose (week 14) of D123-ferritin and D123-
encapsulin, respectively (Figure 5A). Neutralization titers in
gp350 ectodomain-immunized animals were 0.5 to 1.0 log
lower, although the overall antibody binding titers were similar
to that of D123-ferritin and D123-encapsulin-immunized animals
(Figures 5A and 5B). The data confirm the immunogenicity of
gp350-based nanoparticles in a second species and indicate
that antibody production can be enhanced in the presence of
pre-existing immunity.
Protective Immunity against Experimental Challenge
with Recombinant Vaccinia Virus Expressing EBV gp350
To test the efficacy of vaccine-induced immunity in a mouse
challenge model, we employed a recombinant virus challenge
using a vaccinia virus that expressed EBV gp350 (rVV-gp350).
We constructed and characterized rVV-gp350 and titrated the
dose of virus in mice to establish a model in which weight loss
was observed as a result of the infection (Figure S5), as has
been reported with parental vaccinia virus (Chen et al., 2007).
When mice were challenged 2 months after the third immuniza-
tion, all mice immunized with gp350 ectodomain and control
mice, with one exception, lost R30% of their weight within
8 days and required euthanization; however, four out of five of
the D123-ferritin-immunized mice were protected, showing
milder weight loss followed by rapid recovery (Figure 6A,
p = 0.0027 for mice immunized with D123-ferritin versus gp350
ectodomain). We observed similar findings in mice that were
challenged even 10 months after the third immunization (Fig-
ure 6B, p = 0.0210 for mice immunized with D123-ferritin versusAugust 27, 2015 ª2015 Elsevier Inc. 1093
E
nd
po
in
t t
ite
r (
lo
g 1
0)
R
LU
 (l
og
10
)
2
6
5
4
3
6
5
4
3
Injection: 1 2 1 2
ELISA LIPS
IC
50
 ti
te
r (
lo
g 1
0) 4
3
2
1
1 2
Neutralization
Immunogen:
7 5
D 12
3
D 12
3-f
err
itin
D 12
3-e
nc
ap
su
lin
gp
35
0 e
cto
do
ma
inD 12
3
D 12
3-f
err
itin
D 12
3-e
nc
ap
su
lin
gp
35
0 e
cto
do
ma
in D 12
3
D 12
3-f
err
itin
D 12
3-e
nc
ap
su
lin
gp
35
0 e
cto
do
ma
inD 12
3
D 12
3-f
err
itin
D 12
3-e
nc
ap
su
lin
gp
35
0 e
cto
do
ma
in D 12
3
D 12
3-f
err
itin
D 12
3-e
nc
ap
su
lin
gp
35
0 e
cto
do
ma
inD 12
3
D 12
3-f
err
itin
D 12
3-e
nc
ap
su
lin
gp
35
0 e
cto
do
ma
in
A
** ****
********
****
**** ******** ****
********
****
**** ****
********
****
****
********
****
****
********
****
Dose (µg): 5.0 5.0 5.0 5.0 5.0 5.0
5
4
3
2
1
IC
50
 ti
te
r (
lo
g 1
0)
:noitcejnI 321
Weeks
D123-ferritingp350 ectodomain D123-encapsulin
52 0302510150
Immunogen:
1 2 3 1 2 3
0251015052 0302510150 52 03
C
Dose (µg): 5.0 5.0 5.0
B
Injection: 2
Neutralization
IC
50
 ti
te
r (
lo
g 1
0)
4
3
2
1
5
Immunogen:
gp
35
0 e
cto
do
ma
in 
+ f
err
itin
Dose (µg): 5+5 5 5+5 55 5
gp
35
0 e
cto
do
ma
in
D 12
3 +
 fe
rrit
in
D 12
3
Fe
rrit
in
D 12
3-f
err
itin
Figure 4. Immunogenicity of Soluble gp350 Monomer and gp350-Based Nanoparticles
(A) Groups of BALB/c mice (n = 5) were immunized with 5.0 mg of soluble gp350 ectodomain, D123, D123-ferritin, or D123-encapsulin in adjuvant at weeks 0 and 3.
Immune sera were collected 2 weeks after the first (1) and the second (2) immunizations and analyzed by gp350 ELISA, LIPS, and virus neutralization assays.
Endpoint binding titer (left), LIPS relative light units (RLU) (middle), and neutralization IC50 titer (right) were determined. **p < 0.01; ***p < 0.001; ****p < 0.0001.
(B) Neutralization titers frommice 2 weeks after the second immunization with ferritin alone, ferritin mixed with gp350, or D123-ferritin. The data are shown as box-
and-whiskers plots (box indicates lower andupper quartileswith line atmedian, andwhiskers spanminimumandmaximumdatapoints)with individual datapoints.
(C) Kinetics of serum neutralization titers after immunization with gp350 ectodomain or gp350-based nanoparticles. Groups of BALB/c mice (n = 5) were
immunized with 5.0 mg of gp350 ectodomain, D123-ferritin, or D123-encapsulin in adjuvant at weeks 0, 3, and 16. Immune sera were collected periodically after
immunization, and serum neutralization IC50 titers were determined and plotted. Each dot represents an individual mouse. The horizontal dotted line represents
the detection limit of the assay.
See also Figure S4.gp350 ectodomain). Protection was not observed in mice immu-
nized with D123-encapsulin in both experiments (Figures 6A and
6B).We note that themajority of the vaccinia virionswould not be
enveloped by the plasma membrane where the gp350 would be
expressed but instead envelope would be derived from the
endoplasmic reticulum. Hence, anti-gp350 antibody would likely
not completely neutralize the incoming vaccinia virus particles
and allow the incoming virus to infect cells for at least one round
of replication. In contrast, it is more likely that vaccinia virus-
infected cells that express gp350 on the surface are prone to
be killed by antibody-dependent cell cytotoxicity, complement-
dependent cytotoxicity, or cytotoxic T cells. We think that one1094 Cell 162, 1090–1100, August 27, 2015 ª2015 Elsevier Inc.or more of these mechanisms mediate viral clearance in the
vaccinia challenge model. We observed slightly higher neutral-
izing activity and increased binding affinity of anti-gp350 anti-
body in D123-ferritin-immunized groups than in D123-encapsulin
groups (Figures 4C, S4A, and S4B), but the difference was not
statistically significant, suggesting that other mechanisms may
contribute to protection.
Induction of CR2BS-Specific Antibodies by D123
Nanoparticle Immunization
To define the specificity of the antibodies elicited by gp350-
based immunogens, we used a surface plasmon resonance
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(A) Neutralization titers in monkeys immunized
with 50 mg of gp350 ectodomain, 25 mg of
gp350 D123-ferritin, or D123-encapsulin in adjuvant
at weeks 0, 4, and 12. Plasma was collected
prior to immunization and periodically after im-
munization.
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nized monkeys after three immunizations. Each
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limit of the assay. The data are shown as box-and-
whiskers plot with individual data points.(SPR)-based antibody competition assay (McLellan, 2013) (Fig-
ure S6). Strikingly, more than half of the total anti-gp350
antibodies in the sera elicited by either D123-ferritin or D123-en-
capsulin was competed by CR2BS-directed mAb 72A1 when it
was used as a competitor (52% ± 11% or 60% ± 12%, respec-
tively), whereas only 5% ± 4%of antibodies in immune sera from
gp350 ectodomain-immunized animals was blocked by thismAb
(Figures 7A and 7B). This competition demonstrated that the
CR2BS on both D123 nanoparticles was the predominant target
of recognition; however, the same site on the gp350 ectodomain
was not the major target. In addition, these differences were not
due to total levels of gp350 antibody since the ELISA endpoint
titers differ only 2-fold between the three immunization groups
after the second dose (Figure 4A). Interestingly, only a negligible
fraction of anti-gp350 antibodies in the same immune sera was
competed by non-neutralizing, non-CR2BS-directed mAb 2L10
(6% ± 5%, 5% ± 4%, and 12% ± 16% with gp350 ectodomain,
D123-ferritin, and D123-encapsulin, respectively), although 72A1
and 2L10 epitopes were equally available and accessible for im-
mune recognition (Figures 2B, 2C, 7A, and 7B).
To confirm the functional relevance of the CR2BS-directed
antibodies in immune sera, we designed gp350 ectodomain
mutants to abolish CR2 and 72A1 binding (Figure 7C). One
mutant had an extra N-linked glycosylation site at residue 162
(glyc162), and another mutant had two extra glycans at residues
162 and 208 (glyc162/208), as both 162 and 208 have been re-
ported as critical residues for CR2 and 72A1 binding (Szakonyi
et al., 2006; Young et al., 2008). Expectedly, the glycan mutation
at 162 reduced binding to mAb 72A1, and the 162/208 glycans
completely diminished 72A1 recognition, whereas binding of
mAb 2L10 to gp350 wild-type (WT), glyc162, and glyc162/208
remained constant (Figure 7C). When sera frommice immunized
with D123-ferrtin or D123-encapsulin were pre-incubated with
gp350WT to assess virus neutralization, most of neutralizing ac-
tivity was depleted, as all gp350-specific antibodies in sera were
absorbed by excess amount of gp350 WT. In contrast, the 162/
208 glycan mutant absorbed only a small fraction of the neutral-
ization activity, indicating that themajority of neutralization activ-
ity was targeting the site blocked by this mutant (Figure 7D).
These results document the importance of CR2BS-directed
antibodies in virus neutralization. Further, we found increased
serum antibody binding to the CR2BS relative to full-lengthgp350 ectodomain after immunization with D123 nanoparticles
compared to immunization with gp350 ectodomain (Figure 7E),
although the overall antibody binding titers were similar in these
immunization groups (Figures 4A and 5B), thus documenting
preferential elicitation of CR2BS-directed antibodies in both
immunized mice and monkeys.
DISCUSSION
Natural infection with EBV induces a neutralizing antibody
response in the majority of individuals, although the titers are
generally modest (IC50z10
1.5) (Sashihara et al., 2009). The qual-
ity of the immune response is often a key determinant of vaccine-
induced immunity independent of its magnitude. It is noteworthy
that the soluble gp350 ectodomain and D123 do not effectively
induce neutralizing antibodies in mice, unlike the D123 nanopar-
ticles, despite the fact that both soluble and nanoparticle forms
of gp350 have similar antigenic profiles. This observation high-
lights the importance of antigen presentation, specifically the
conformational authenticity of functional domains, in deter-
mining the quality of the immune response (McLellan, 2013). Im-
mune focusing through nanoparticle presentation of selective
domains of gp350 enabled elicitation of antibody predominantly
to CR2BS, providing a mechanism of potent neutralization in
sera. The mode of neutralization targeting the receptor-binding
site (RBS) has been described in other viruses. The VRC01-
class of antibodies that bind the CD4-binding site of the enve-
lope of human immunodeficiency virus 1 (HIV-1) potently
neutralize >90% of circulating viral strains regardless of their
sequence variability (Wu et al., 2010; Zhou et al., 2010). MAbs
CH65 (Whittle et al., 2011), C05 (Ekiert et al., 2012), and some
others neutralize influenza A viruses through the conserved sialic
acid-binding site on a viral hemagglutinin. Certain mAbs to hep-
atitis C virus (Krey et al., 2013), poliovirus (Chen et al., 2011,
2013), herpes simplex virus (Lee et al., 2013), and severe acute
respiratory syndrome (SARS) coronavirus (van den Brink et al.,
2005) also use a similar mechanism to neutralize viruses. Since
the RBS must be functionally conserved to engage its host cell
receptor, it is one of the most vulnerable targets of the virus.
However, isolated RBS-containing domains (or RBDs) are often
weakly immunogenic due to steric hindrance from surrounding
glycans, hypervariability near the RBS that impairs targeting byCell 162, 1090–1100, August 27, 2015 ª2015 Elsevier Inc. 1095
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Figure 6. Protective Immunity against an
Experimental Infection with Recombinant
Vaccinia Virus Expressing EBV gp350
in Mice
(A and B) Kaplan-Meier survival curve and body
weight change after recombinant gp350-vaccinia
virus challenge. Mice (n = 5) were immunized with
5.0 mg of gp350 ectodomain, gp350 D123-ferritin,
or D123-encapsulin at weeks 0, 3, and 16 and were
challenged at 2 months after the final immuniza-
tion (A) or immunized three times with 0.5 mg of
vaccines and challenged at 10 months after the
final immunization (B). Summary of p values be-
tween groups (generated by log-rank Mantel-Cox
test) is shown in each panel (ns, not significant).
Mock, irrelevant nanoparticle-immunized mice
(n = 5); control, age-matched naive mice (n = 5).
See also Figure S5.the immune system, or altered conformation (Georgiev et al.,
2013; Joyce et al., 2013; Julien et al., 2012).
Extensive glycosylation of EBV gp350 is thought to regulate
the immune response to the glycoprotein (Machiels et al.,
2011; Serafini-Cessi et al., 1989). One of the principles of recom-
binant vaccine design is to improve immunogenicity of the native
protein by modifying and/or altering its function/configuration,
otherwise impossible to apply to certain other vaccine platforms
(e.g., killed or attenuated virus). Truncation of the COOH-termi-
nal 480 residues of gp350 to make the D123 variant almost
completely removed the ‘‘mucin-like’’ O-linked glycan-rich
domain from the protein; however, this truncation led to protein
mis-folding and/or destabilization in a soluble form. Improve-
ment of immunogenicity was observed only when gp350 D123
was displayed on ferritin or encapsulin nanoparticles, suggesting
that the D123 was conformationally stabilized on the nanopar-
ticles without the remainder of the gp350 domain(s).
The diameter of D123-ferritin and D123-encapsulin particles are
within 20–50 nm, and therefore both are likely to traffic through
lymph nodes similarly, where they would be taken up by den-
dritic cells, B cells, and macrophages (Irvine et al., 2013). One
potential explanation for the difference in immunogenicity is
the orientation of gp350RBS relative to the surface of the particle1096 Cell 162, 1090–1100, August 27, 2015 ª2015 Elsevier Inc.and the packing density. These parame-
ters would be quite different between
ferritin and encapsulin and could affect
the accessibility and angle of approach
by immune receptors. On ferritin, the
RBS is presented upright and spaced
within 50–100 A˚. This distance would
allow crosslinking of B cell receptors
(BCR) and would enhance signal trans-
duction through downstream molecules
to stimulate B cell activation (Bachmann
and Zinkernagel, 1997). It also remains
possible that the dimerization of D123
seen in ferritin effectively limits the sol-
vent-exposed surface of non-RBS sites
and focuses the immune response tothe RBS more efficiently. Recent advances in nanoparticle tech-
nology further accentuate the benefits of symmetrically arrayed
antigens to activate B cells through low-affinity BCRs (Jardine
et al., 2013; Lingwood et al., 2012) and improve vaccine-induced
immunity (Kanekiyo et al., 2013). These technologies allowed us
to design immunogens that elicit immune response to targets
otherwise difficult to be induced by native protein such as the
CR2BS on gp350.
Self-assembling nanoparticle-based EBV vaccine candidates
displaying the receptor-binding portion of gp350 elicited potent
neutralizing activity in mice and non-human primates by pre-
cisely targeting the site of vulnerability of the virus and stimulated
neutralizing antibody responses that significantly exceeded the
level obtained with soluble gp350 protein. We anticipate that
this synthetic approach to design immunogens offers novel op-
portunities to create and/or redesign vaccines against patho-
gens for which it has been difficult to induce effective immunity.EXPERIMENTAL PROCEDURES
Gene Synthesis and Vector Construction
The gene encoding Helicobacter pylori-bullfrog hybrid ferritin was constructed
by fusing residues 2–9 of bullfrog (Rana catesbeiana) ferritin lower subunit
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Figure 7. Detection of CR2BS-Directed
Antibodies in Immune Sera
(A) SPR-based cross-competition assay of im-
mune sera with mAbs. Binding of immune sera
(after the second immunization) to the mAb-satu-
rated gp350 was measured by Biacore. Each
curve represents an individual serum. All data
were normalized with C179-saturated curves and
are shown as fraction response. Cross-competi-
tion of immune sera by 72A1 (left) and 2L10 (right)
are shown for different immunization groups.
(B) Specificity of gp350-binding antibodies in im-
mune sera. Percent inhibition of serum antibodies
to bind gp350 by 72A1 or 2L10 was calculated.
(C) Generation of EBV gp350 CR2BS mutants.
The gp350 domains I and II are shown in blue and
sky blue, respectively. Attached glycans are shown
as yellow spheres. Residues 162 and 208 are
shown in red, and inferred CR2BS is indicated
(PDB:2H6O) (left).Bindingofgp350WTandCR2BS
mutants tomAbs 72A1 and 2L10 wasmeasured by
ELISA (right). Each symbol represents mean ± SD.
(D) Serum neutralization titers determined in the
absence (closed circle) or presence of gp350
WT (open circle) and glyc162/208 (open square)
proteins.
(E) Preferential elicitation of antibody response to
CR2BS in mice and monkeys. Serum antibody
response to either gp350 WT or glyc162/208 was
measured after the second immunization with
indicated immunogens. Endpoint ELISA antibody
titers for both gp350 WT and glyc162/208 were
determined, and ratios of those titers were
calculated (WT ⁄ glyc162/208).
The data in (B), (D), and (E) are shown as box-and-
whiskers plots with individual data points. *p <
0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. See
also Figure S6.(UniProt: P07797 with a N8Q mutation to abolish a potential N-glycosylation
site) to H. pylori nonheme ferritin (UniProt: Q9ZLI1, residues 3–167) with an
I7Emutation to preserve the conserved salt bridge found in human and bullfrog
ferritins (6R and 14E in both human light chain and bullfrog lower-subunit fer-
ritins) with 6R of bullfrog ferritin. Mutation N19Q was introduced in H. pylori
ferritin to abolish a potential N-glycosylation site. The secreted encapsulin
was constructed by fusing a human CD5 signal to Termotoga maritima encap-
sulin (UniProt: Q9WZP2, residues 1–264). The gene encoding EBV strain B95-8
gp350 (UniProt: P03200, residues 1–907) was synthesized, and the fragments
corresponding to ectodomain (residues 2–860), analogous to the region used
in the crystal structure (Szakonyi et al., 2006) (D2H6O, residues 2–470), D123
(residues 2–425) and D12 (residues 2–317) were amplified. The fragments
were inserted between a bovine prolactin signal (bPRL) and hybrid ferritin or
were fused to 30 end of encapsulin with a (SG3)2 linker to give rise to gp350-
ferritin and gp350-encapsulin, respectively. Soluble gp350 ectodomain and
D123 were constructed by fusing corresponding fragments with bPRL
and COOH-terminal hexa-histidine tag. The CR2BS mutant gp350s were
made by introducing N-glycosylation sites at 162 (W162N/N164T) and 208Cell 162, 1090–1100,(D208N/E210T). All genes were then cloned into
the CMV/R 8kb (VRC 8405) mammalian expres-
sion vector for protein production.
Biosynthesis of Recombinant Proteins and
Purification
The expression vectors were transiently trans-
fected into FreeStyle 293F or Expi293F cells using293fectin or ExpiFectamine 293 transfection reagents, respectively (Life Tech-
nologies). The gp350-based nanoparticleswere purified by affinity chromatog-
raphy using Galanthus nivalis agglutinin resins (EY Laboratories) followed by
size exclusion chromatography with a HiPrep 16/60 Sephacryl S-500 HR
column (GE Healthcare). The soluble gp350 proteins were purified using Ni
sepharose excel resin (GE Healthcare) followed by size exclusion chromatog-
raphy with a Superdex 200 10/300 GL (GE Healthcare).
Electron microscopy and cryo-EM reconstruction
For negative stain electron microscopy (EM), samples of about 50 mg ml1
were adsorbed to freshly glow-discharged carbon-coated grids and stained
with 2% ammonium molybdate. Images were recorded on an FEI T20 micro-
scope with an Eagle CCD camera. For cryo-EM, samples (5 mg ml1, 3 ml)
were applied to holey grids (Quantifoil) and fast-frozen in liquid ethane, as
described previously (Meng et al., 2013). Cryo-EM images of the D123-ferritin
and D123-encapsulin were acquired on an FEI Titan Krios operated at
300 keV and a CM200 FEG microscope operated at 200 keV, respectively.
Image processing and three-dimensional reconstruction were performedAugust 27, 2015 ª2015 Elsevier Inc. 1097
using 1,000 particles with the EMAN suite of programs (Baker et al., 2010).
The final reconstruction was computed and was low-pass filtered to 30 A˚ in
resolution. The fit model was made using the EMFit program (Rossmann
et al., 2001).
Immunization
Animal experiments were carried out in accordance with all federal regulations
and NIH guidelines and were approved by the Institutional Animal Care and
Use Committee. Eight- to 10-week old female BALB/c mice (Charles River
Laboratories) were immunized (n = 5) intramuscularly with 5 or 0.5 mg of puri-
fied proteins in 100 ml of 50% (v/v) mixture of SAS adjuvant (Sigma) in PBS at
weeks 0, 3, and 16. For the non-human primate study, eight cynomolgus
macaques (Macaca fascicularis) were immunized with 50 mg (gp350 ectodo-
main) or 25 mg (D123-ferritin or D123-encapsulin) in SAS adjuvant intramuscu-
larly at weeks 0, 4, and 12.
GFP-Reporter Virus Neutralization Assay
Neutralization of EBV to B cells has been described previously (Sashihara
et al., 2009). Briefly, immune sera were serially diluted and incubated with
B95-8/F reporter virus (GFP-reporter EBV) for 2 hr. For protein competition
neutralization, sera were preincubated with either soluble gp350 WT or
glyc162/208 mutant protein (25 mg ml1) for 30 min. The mixture was added
to Raji cells and incubated for 3 days. Cells were fixed and analyzed with an
Accuri C6 flow cytometer (BD Biosciences). Neutralization antibody titers
were expressed as the concentration of serum antibody needed to inhibit viral
entry by 50% (IC50).
Recombinant Vaccinia Virus Challenge
Full-length EBV gp350was cloned into pRB21, a plasmid encoding vaccinia vi-
rus (VV) vp37, which is required for plaque formation (Blasco andMoss, 1995).
BSC-1 cells were infected with VV vRB12 (Dvp37) and subsequently trans-
fected with pRB21 containing EBV gp350. Recombinant virus (rVV-gp350)
was rescued and purified by plaque purification. Challenge stock was purified
on a cushion of 36% sucrose by ultracentrifugation (32,900 3 g, 80 min)
and titrated in BSC-1 cells. Immunized mice were challenged intranasally
with13106PFUof virus (10ml per nostril).Miceweremonitoredandeuthanized
when they lostR30% of their pre-challenge weight or suffered symptoms.
Surface Plasmon Resonance-Based Antibody Competition
Soluble gp350 WT protein was immobilized on a CM5 sensor chip (GE Health-
care). Fifty microliters (100 mg ml1) of mAb (72A1, 2L10, or C179) were flowed
over the chip at 30 ml min1 before injecting 50 ml of the serum samples (1/50
dilution) at 30 ml ml1 on a Biacore 3000 instrument (GE Healthcare). The chip
was regenerated using 3M MgCl2 after each run.
Statistical Analysis
p values were generated by one-way ANOVA using the Prism 5 program
(GraphPad Software) unless reported otherwise.
Molecular Representations
All structural renderings of proteins were generated using the UCSF Chimera
package, version 1.8 (http://www.cgl.ucsf.edu/chimera/). The UCSF Chimera
is developed by the Resource for Bio-computing, Visualization, and Infor-
matics at the University of California, San Francisco (supported by NIGMS
P41-GM103311).
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